Clinical trial
Multicenter, First-line Metastatic Open-label Prospective Phase II Trial Evaluating the Combination of Palbociclib (CDK 4/6 Inhibitor) and Hormone Therapy (Letrozole or Anastrozole) in Women With Luminal, HER2 Negative Advanced Breast Cancer: Evaluation of the Prediction of Individual Treatment Efficacy Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies (Quantum Optics).
NCT05190094 is registered in ClinicalTrials.gov with International Cancer Research Group, United Arab Emirates as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, First-line Metastatic Open-label Prospective Phase II Trial Evaluating the Combination of Palbociclib (CDK 4/6 Inhibitor) and Hormone Therapy (Letrozole or Anastrozole) in Women With Luminal, HER2 Negative Advanced Breast Cancer: Evaluation of the Prediction of Individual Treatment Efficacy Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies (Quantum Optics).
- Lead sponsor
- International Cancer Research Group, United Arab Emirates
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 20, 2022
- Completion date
- June 30, 2026
- Enrollment
- 80 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
hormonal receptors positive, her2 negative, advanced breast cancer